LETTER {#sec1}
======

The deluge of data produced by the Xpert MTB/RIF test (Cepheid) can help improve global rifampin-resistant tuberculosis (RR-TB) control strategies through molecular epidemiological surveillance ([@B1], [@B2]). Recently, a new version of the test, Xpert Ultra (hereinafter called Ultra), was released ([@B3]). Determining the relationship between RR-conferring *rpoB* mutations, Ultra probes, and melting temperature shifts (Δ*T~m~*), i.e., the difference between mutant and wild-type melting temperatures, allows Ultra results to be utilized for rapid detection of RR-TB strains and related underlying *rpoB* mutations.

To determine the reliability of Ultra results for predicting specific mutations, we tested 13 rifampin-susceptible (RS)-TB strains and 104 RR-TB strains harboring 33 unique RR-conferring mutations from the Belgian Coordinated Collections of Microorganisms in the Institute of Tropical Medicine Antwerp according to a protocol previously described ([@B2]) (see the supplemental material). Of note, the Glu250Gly (*n* = 2) and Arg299Cys (*n* = 1) mutations were among the RS-TB strains. We then compared Ultra raw results with available *rpoB* sequences of the strains.

Overall, 29/30 (97%) mutations inside the rifampin resistance-determining region (RRDR) were correctly identified by Ultra. Of concern, mutation His445Arg gave a "RIF Resistance Indeterminate" result among 3/4 strains tested, while it was reported as RR in the initial validation study ([@B3]). The silent mutation Thr444Thr was not reported as RR ([Fig. 1](#F1){ref-type="fig"}). The RR-conferring mutations on codons 170 and 491 situated outside the RRDR were not detected.

![Overview of Xpert Ultra test results. The observed probe reactions for each RRDR mutation were laid over the claimed probe coverage (light gray). Shown in black are probe reactions concordant with manufacturer claims, in blue are probe reactions missed by one probe but captured by another probe, and in red is a probe reaction representing a "RIF Resistance Indeterminate" result from 3 out of 4 strains tested. Results in the hatched pattern were superimposed for greater visibility.](zjm9990960710001){#F1}

The probe reactions observed were largely in agreement with previous results ([@B3]), although we noted that mutations Met434Val, Met434Thr, and those in codon 435 were captured only by probe rpoB2, Ser450Leu and Ser450Trp were captured by both probe rpoB3 and probe rpoB4a, His445Arg was captured only by probe rpoB3, and Lys446Gln was captured only by probe rpoB4.

All mutations except those in codon 450 were associated with a negative Δ*T~m~* ([Fig. 2](#F2){ref-type="fig"}). The combination of Δ*T~m~* values with the capturing probes enabled us to differentiate mutations in codons 430, 431, 434, 435, 441, 446, 450, and 452, including disputed mutations ([@B4]) ([Table 1](#T1){ref-type="table"}). Mutation Asp435Tyr was unambiguously distinguished from Asp435Val with the ∣Δ*T~m~*∣ of probe rpoB2, while mutations Ser441Gln and Ser441Leu were discriminated from the rest by the ∣Δ*T~m~*∣ values of probes rpoB2 and rpoB3. Mutations His445Asp and His445Tyr were distinguished from disputed mutations His445Leu and His445Asn through the ∣Δ*T~m~*∣ of probe rpoB3. Ser450Leu was distinguished from Ser450Trp by the ∣Δ*T~m~*∣ of probe rpoB4A. The indeterminate result associated with His445Arg may be caused by its ∣Δ*T~m~*∣ being equal to 1.8°C, unlike the ∣Δ*T~m~*∣ values for other mutations, which typically exceed 2°C. Our recent experience with Ultra on diagnostic sputum samples pertained only to the Ser450Leu and His445Asp mutations, for which the Δ*T~m~* corresponded exactly with the Δ*T~m~* that we observed for bacterial thermolysates. This should be validated more extensively, which is beyond the scope of our present study.

![Melting temperature shifts (Δ*T~m~*s) observed upon detection of a rifampin resistance (RR)-conferring *rpoB* mutation in the RR-determining region (RRDR) by Xpert Ultra. The *y* axis reflects the melting temperature difference (Δ*T~m~*) between mutant and wild-type probe-amplicon hybrids, while the *x* axis shows the mutations that we tested. The data points on the graph are Δ*T~m~* values grouped by their associated Ultra probes (differentiated by color), which correspond to a specific *rpoB* mutation. *x* axis labels in brown are disputed mutations.](zjm9990960710002){#F2}

###### 

Xpert Ultra raw results[^*a*^](#T1F1){ref-type="table-fn"}

  Mutation(s)[^*b*^](#T1F2){ref-type="table-fn"}   No. of strains tested   Nucleotide change(s)        Xpert Ultra probe(s)   Wild-type*T*~*m*~ range(s) (mean\[s\])                     Mutant *T*~*m*~ range(s)             ∣Δ*T*~*m*~∣ mean(s) or range(s)
  ------------------------------------------------ ----------------------- --------------------------- ---------------------- ---------------------------------------------------------- ------------------------------------ ---------------------------------
  Val170Phe                                        3                       GTC→TTC                     ND                     ND                                                         ND                                   ND
  Glu250Gly^\#^                                    2                       GAG→GGG                     ND                     ND                                                         ND                                   ND
  Arg299Cys^\#^                                    1                       CGC→TGC                     ND                     ND                                                         ND                                   ND
  \**Leu430Pro*                                    8                       CTG→CCG                     rpoB1                  69.1--69.5 (69.3)                                          63.0--63.4                           5.9--6.3
  [*Leu430Pro*]{.ul} + \*Met434Ile                 1                       CTG→CCG; ATG→ATA            rpoB1; rpoB2           69.1--69.5 (69.3); 72.8--73.2 (73)                         63.2; 69.8                           6.1; 3.2
  [*Leu430Pro*]{.ul} + Met434Val                   1                       CTG→CCG; ATG→GTG            rpoB1                  69.1--69.5 (69.3)                                          63.0                                 6.3
  [*Leu430Pro*]{.ul} + His445Gln                   1                       CTG→CCG; CAC→CAG            rpoB1; rpoB3           69.1--69.5 (69.3); 75.5--76.0 (75.75)                      63.5; 72.2                           5.8; 3.6
  [*Leu430Pro*]{.ul} + His445Gln                   1                       CTG→CCG; CAC→CAA            rpoB1; rpoB3           69.1--69.5 (69.3); 75.5--76.0 (75.75)                      63.1; 71.7                           6.2; 4.1
  [Asp435Gly]{.ul} + Met434Thr                     1                       GAC→GGC; ATG→ACG            rpoB2                  72.8--73.2 (73)                                            69.7                                 3.3
  \*Asp435Phe                                      1                       GAC→TTC                     rpoB2                  72.8--73.2 (73)                                            67.7                                 5.3
  *\*Asp435Tyr*                                    11                      GAC→TAC                     rpoB2                  72.8--73.2 (73)                                            68.6--69.0                           4.0--4.4
  [*Asp435Tyr*]{.ul} + Asn437Asp                   1                       GAC→TAC; AAC→GAC            rpoB2                  72.8--73.2 (73)                                            66.6                                 6.4
  [*Asp435Tyr*]{.ul} + Met434Ile                   1                       GAC→TAC; ATG→ATT            rpoB2                  72.8--73.2 (73)                                            68.5                                 4.5
  \*Asp435Val                                      5                       GAC→GTC                     rpoB2                  72.8--73.2 (73)                                            69.3--69.5                           3.5--3.7
  [Asp435Val]{.ul} + Gln432Glu                     1                       GAC→GTC; CAA→GAA            rpoB2; rpoB1           72.8--73.2 (73); 69.1--69.5 (69.3)                         70.5; 65.9                           2.5; 3.4
  \*Ser441Gln                                      1                       TCG→CAG                     rpoB2; rpoB3           72.8--73.2 (73); 75.5--76.0 (75.75)                        68.3; 73.5                           4.7; 2.3
  \*Ser441Leu                                      1                       TCG→TTG                     rpoB2; rpoB3           72.8--73.2 (73); 75.5--76.0 (75.75)                        70.0; 73.5                           3.0; 2.3
  His445Gly                                        1                       CAC→GGC                     rpoB3                  75.5--76.0 (75.75)                                         70.9                                 4.9
  His445Thr                                        1                       CAC→ACC                     rpoB3                  75.5--76.0 (75.75)                                         70.9                                 4.9
  His445Ser                                        1                       CAC→AGC                     rpoB3                  75.5--76.0 (75.75)                                         71.1                                 4.7
  His445Ser + \*Lys446Gln + Thr444Thr              1                       CAC→TCC; AAG→CAG; ACC→ACG   rpoB4B                 67.0--67.6 (67.3)                                          62.3                                 5.0
  His445Asp                                        3                       CAC→GAC                     rpoB3                  75.5--76.0 (75.75)                                         71.9--72.1                           3.7--3.9
  *His445Leu*                                      2                       CAC→CTC                     rpoB3                  75.5--76.0 (75.75)                                         72.2--72.3                           3.5--3.6
  *His445Asn*                                      2                       CAC→AAC                     rpoB3                  75.5--76.0 (75.75)                                         72.3--72.4                           3.4--3.5
  [*His445Asn*]{.ul} + \*Asp435Glu                 1                       CAC→AAC; GAC→GAA            rpoB3; rpoB2           75.5--76.0 (75.75); 72.8--73.2 (73)                        72.4; 70.2                           3.4; 2.8
  His445Tyr                                        4                       CAC→TAC                     rpoB3                  75.5--76.0 (75.75)                                         72.5--72.6                           3.2--3.3
  \*His445Arg                                      4                       CAC→CGC                     rpoB3                  75.5--76.0 (75.75)                                         73.9                                 1.9
  [His445Arg]{.ul} + Ser428Arg                     1                       CAC→CGC; AGC→AGG            rpoB1                  69.1--69.5 (69.3)                                          65.8                                 3.5
  Ser450Phe                                        1                       TCG→TTC                     rpoB3                  75.5--76.0 (75.75)                                         71.8                                 4.0
  \*Ser450Leu                                      14                      TCG→TTG                     rpoB3; rpoB4A          75.5--76.0 (75.75); 67.0--67.6 (67.3)                      72.9--73.3; 73.3--73.8               2.5--2.9; 6.0--6.5
  [Ser450Leu]{.ul} + Thr482Asn                     2                       TCG→TTG; ACC→AAC            rpoB2; rpoB3; rpoB4A   72.8--73.2 (73); 75.5--76.0 (75.75); 67.0--67.6 (67.3)     69.2--69.5; 73.1--73.3; 73.6--73.7   3.5--3.8; 2.5--2.7; 6.3--6.4
  [Ser450Leu]{.ul} + Ile491Val                     2                       TCG→TTG; ATC→GTC            rpoB2; rpoB3; rpoB4A   72.8--73.2 (73); 75.5--76.0 (75.75); 67.0--67.6 (67.3)     70.0; 73.2--73.3; 73.6--73.7         3.0; 2.5--2.6; 6.3--6.4
  \*Ser450Trp                                      3                       TCG→TGG                     rpoB3; rpoB4A          75.5--76.0 (75.75); 67.0--67.6 (67.3)                      73.1--73.5; 70.6--71.0               2.3--2.7; 3.3--3.7
  [Ser450Trp]{.ul} + \*Ser431Gly                   1                       TCG→TGG; AGC→GGC            rpoB3; rpoB4A; rpoB1   75.5--76.0 (75.75); 67.0--67.6 (67.3); 69.1--69.5 (69.3)   73.2; 70.7; 66.4                     2.6; 3.4; 2.9
  *\*Leu452Pro*                                    12                      CTG→CCG                     rpoB4B                 67.0--67.6 (67.3)                                          61.2--61.6                           5.7--6.1
  *Ile491Phe*                                      10                      ATC→TTC                     ND                     ND                                                         ND                                   ND

Capturing probes, wild-type melt peak temperature (*T*~*m*~) ranges and means, mutant *T*~*m*~ ranges, and absolute values of melting temperature shift (Δ*T*~*m*~) ranges associated with specific *rpoB* mutations in the strains tested and the corresponding nucleotide changes. ND, strains that harbored corresponding mutations outside the RRDR yielded a "RIF Resistance Not Detected" result. \*, rifampin resistance-determining region (RRDR) mutation unambiguously identified by unique combinations of Ultra probes and Δ*T*~*m*~s, including disputed ones (in italics). ^\#^, rifampin susceptible according to phenotypic testing.

For double mutants, the high-confidence RR-conferring mutations are underlined ([@B6], [@B7]).

Our findings confirm the ability of Ultra to unambiguously identify a wide range of RRDR mutations. With the unprecedented rollout of Xpert MTB/RIF and associated connectivity solutions, such as DataToCare (Savics, Belgium) and GXAlert (SystemOne, USA) ([@B2]), Ultra results may allow us to rule out transmission between RR-TB patients in a specific setting (Fig. S1), distinguish relapse from reinfection ([@B5]) (Fig. S2), and resolve discordance between an RR Ultra result and a low-level RS phenotypic result due to a disputed mutation. For such applications, it is key that Δ*T~m~* values are included in the exported results.
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